Introduction: The progressive understanding of the molecular and biochemical alterations of renal cell carcinoma (RCC) has drastically changed the course of this tumor through the development of new molecular targeted drugs. Furthermore, an increasing knowledge of disease molecular pathways and genetic mutations are turning RCC in different kind of tumors each one with different clinical behaviours, outcomes and treatment chances. Areas covered: After angiogenetic inhibitors which are the current first treatment choice other target drugs are emerging as agents able to improve survival of patients with RCC. However, since that RCC involves different kind of tumors resulting by specific gene alterations the choice of the most favourable treatment could be difficult. Expert commentary: Which factors must be considered before planning treatment strategy? May a better genetic disease knowledge be a support able to help clinicians during decision making and tailored drugs development? These questions are an open challenge whose responses could revolutionise the course of this disease.
Ciccarese C., Di Nunno V., Montironi R., Fiorentino M., Brunelli M., Tortora G., et al. (2016). The role of precision medicine for the treatment of metastatic renal cell carcinoma. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 1(4), 369-377 [10.1080/23808993.2016.1214057].
The role of precision medicine for the treatment of metastatic renal cell carcinoma
Fiorentino M.;Ardizzoni A.;Massari F.
Ultimo
2016
Abstract
Introduction: The progressive understanding of the molecular and biochemical alterations of renal cell carcinoma (RCC) has drastically changed the course of this tumor through the development of new molecular targeted drugs. Furthermore, an increasing knowledge of disease molecular pathways and genetic mutations are turning RCC in different kind of tumors each one with different clinical behaviours, outcomes and treatment chances. Areas covered: After angiogenetic inhibitors which are the current first treatment choice other target drugs are emerging as agents able to improve survival of patients with RCC. However, since that RCC involves different kind of tumors resulting by specific gene alterations the choice of the most favourable treatment could be difficult. Expert commentary: Which factors must be considered before planning treatment strategy? May a better genetic disease knowledge be a support able to help clinicians during decision making and tailored drugs development? These questions are an open challenge whose responses could revolutionise the course of this disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
